An Exploratory Phase II Study to Determine the Safety, Tolerability and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Adults With Diagnostic and Statistical Manual Version 5 (DSM-5) Intermittent Explosive Disorder (IED)
Phase of Trial: Phase II
Latest Information Update: 31 Oct 2019
Price : $35 *
At a glance
- Drugs SRX 246 (Primary)
- Indications Impulse control disorders
- Focus Adverse reactions
- Sponsors Azevan Pharmaceuticals
- 14 Sep 2016 Results published in an Azevan Pharmaceuticals media release.
- 14 Jun 2016 Status changed from active, no longer recruiting to completed.
- 09 May 2016 According to Azevan media release, results are expected in the second quarter.